Inclusion Criteria:

- Written informed consent

- At least 18 years old

- Histologically- or cytologically-confirmed diagnosis of predominantly nonsquamous
cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLC

- No prior systemic first-line therapy for advanced NSCLC

- Measurable disease

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Life expectancy of at least 12 weeks

- Able to swallow and retain oral medication

- Adequate organ system function (hematological, hepatic, and renal)

- Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR
childbearing potential, and agrees to use adequate contraception. A male with a
female partner of childbearing potential is eligible if he uses a barrier method of
contraception or abstinence during the study

Exclusion Criteria:

- Active malignancy or any malignancy in the 3 years prior to first dose of study drug
other than NSCLC

- Central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for
asymptomatic, previously treated CNS metastases

- Clinically significant gastrointestinal abnormalities

- Prolongation of corrected QT interval (QTc) > 480 msecs

- History of any one or more cardiovascular conditions within the past 6 months prior
to randomization

- Poorly controlled hypertension

- History of cerebrovascular accident (including transient ischemic attacks), pulmonary
embolism or untreated deep venous thrombosis (DVT) within the past 6 months

- Major surgery or trauma within 28 days or any non-healing wound, fracture, or ulcer

- Evidence of active bleeding or bleeding diathesis

- Recent hemoptysis

- Endobronchial lesions and/or lesions infiltrating major pulmonary vessels

- Serious and/or unstable pre-existing medical (e.g., uncontrolled infection),
psychiatric, or other condition that could interfere with subject's safety, provision
of informed consent, or compliance to study procedures

- Use of any prohibited medication

- Use of an investigational agent within 28 days or 5 half-lives, whichever is longer,
prior to the first dose of study drug

- Ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is
progressing in severity except alopecia

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to pazopanib, pemetrexed, and/or cisplatin

- Inability to interrupt aspirin or other non-steroidal anti-inflammatory drugs during
the study

- Inability or unwillingness to take folic acid, vitamin B12 supplementation, or
dexamethasone

- Clinically significant third-space fluid collections (e.g., ascites or pleural
effusions) that cannot be controlled by drainage or other procedures prior to study
start

- Recent or concurrent yellow fever vaccination